Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10791401	
Filing Date		2004-03-02	
First Named Inventor	Yuzuru Fukushima		
Art Unit		1745	
Examiner Name			
Attorney Docket Number		09792909-5824	

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Pat of cited Docu	entee or Applicant iment	Releva	Columns,Lines whe ant Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pat of cited Docu	entee or Applicant iment	Releva	Columns,Lines whe ant Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	n citatio	n information p	olease click the Ad	d button	Add	
				FOREIG	GN PA1	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releval Figures Appear	TE
	1	2001-057234	JP			2001-02-27	Mitsui Chemicals In	nc.		×
	2	2001-155790	JP			2001-06-08	Sony Corp			×
	3	2001-167797	JP			2001-06-22	Sony Corp			×

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10791401	
iling Date		2004-03-02	
irst Named Inventor	Yuzur	u Fukushima	
Art Unit		1745	
xaminer Name			
Attorney Docket Number		09792909-5824	

		4	2002-015771	JP		2002-01-18	Toshiba Corp		×
		5	2002-324580	JP		2002-11-08	Mitsubishi Chemicals Corp		×
		6	2003-100299	JP		2003-04-04	TDK Corp		×
	If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS							Remove		

Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (initials* No publisher, city and/or country where published.

1 Japanese Office Action dated December 9, 2006

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Date Considered

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kint Codes of USPTO Patent Documents at year (LSPTO_GOL) or MEPE 901.04. 2 Enter office that issued the document, by the two-letter office (WIPO_Standard ST3.). For Suppresse patent of counters, the includation of the year of the register of the Emport many precise the serial results of patent document.
**Indirect Occurrent by the appropriate symbols as indicated on the document under WIPO Standard ST3.16 if possible, **Deplicant is to place a check mark here it
Employsh language streamlistion as attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10791401	
Filing Date		2004-03-02	
First Named Inventor	Yuzuru Fukushima		
Art Unit		1745	
Examiner Name			
Attorney Docket Numb	ec	09792909-5824	

CERTIFICATION STATEMENT

That each item of information co	ntained in the information disclosure statement	was first cited in any communication

from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	Date (YYYY-MM-DD)
Name/Print	Registration Number

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Officer, U.S. perpartment of Commence, P. 0. Box 1445, Alexandria, V.3.2311-4450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.